DK3565844T5 - Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer - Google Patents

Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer Download PDF

Info

Publication number
DK3565844T5
DK3565844T5 DK18704101.7T DK18704101T DK3565844T5 DK 3565844 T5 DK3565844 T5 DK 3565844T5 DK 18704101 T DK18704101 T DK 18704101T DK 3565844 T5 DK3565844 T5 DK 3565844T5
Authority
DK
Denmark
Prior art keywords
antibodies
methods
treating cancer
cancer
treating
Prior art date
Application number
DK18704101.7T
Other languages
Danish (da)
English (en)
Other versions
DK3565844T3 (da
Inventor
David Jenkins
Ellie Im
Allene Diaz
Sharon Lu
Haley A Laken
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Application granted granted Critical
Publication of DK3565844T3 publication Critical patent/DK3565844T3/da
Publication of DK3565844T5 publication Critical patent/DK3565844T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18704101.7T 2017-01-09 2018-01-09 Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer DK3565844T5 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762444336P 2017-01-09 2017-01-09
US201762477423P 2017-03-27 2017-03-27
US201762491220P 2017-04-27 2017-04-27
US201762556386P 2017-09-09 2017-09-09
PCT/US2018/013029 WO2018129559A1 (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies

Publications (2)

Publication Number Publication Date
DK3565844T3 DK3565844T3 (da) 2023-05-01
DK3565844T5 true DK3565844T5 (da) 2024-09-02

Family

ID=61188903

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18704101.7T DK3565844T5 (da) 2017-01-09 2018-01-09 Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer

Country Status (21)

Country Link
US (2) US11407830B2 (OSRAM)
EP (2) EP3565844B8 (OSRAM)
JP (2) JP7110206B6 (OSRAM)
KR (1) KR102606252B1 (OSRAM)
CN (1) CN110382545A (OSRAM)
AU (2) AU2018206481B2 (OSRAM)
BR (1) BR112019014187A2 (OSRAM)
CA (1) CA3049440A1 (OSRAM)
DK (1) DK3565844T5 (OSRAM)
ES (1) ES2945745T3 (OSRAM)
FI (1) FI3565844T3 (OSRAM)
HU (1) HUE061842T2 (OSRAM)
IL (1) IL267804B2 (OSRAM)
MA (1) MA47208A (OSRAM)
MX (1) MX2019008207A (OSRAM)
PL (1) PL3565844T3 (OSRAM)
PT (1) PT3565844T (OSRAM)
SG (2) SG10201913075RA (OSRAM)
TW (1) TWI767976B (OSRAM)
WO (1) WO2018129559A1 (OSRAM)
ZA (1) ZA201904316B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102057272B (zh) 2008-04-09 2015-02-18 健泰科生物技术公司 用于免疫相关疾病的治疗的新组合物和方法
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018085468A1 (en) * 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
KR20200067164A (ko) 2017-10-06 2020-06-11 테사로, 인코포레이티드 조합 요법 및 그의 용도
EP3752180A4 (en) 2018-02-13 2021-12-15 Merck Sharp & Dohme Corp. METHOD OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
TWI853841B (zh) 2018-10-03 2024-09-01 美商提薩羅有限公司 尼拉帕尼（niraparib）鹽
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
US20200199567A1 (en) * 2018-12-20 2020-06-25 Medimmune, Llc Methods for selection and expansion of t cells expressing pd-1
CN119700933A (zh) * 2019-05-31 2025-03-28 Alx肿瘤生物技术公司 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法
IL293753A (en) 2019-12-18 2022-08-01 Tesaro Inc Biopharmaceutical preparations and related methods
WO2021136523A1 (zh) * 2019-12-31 2021-07-08 甫康（上海）健康科技有限责任公司 一种用于治疗肿瘤的药物组合及其应用
CA3167689A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
CN114902048A (zh) * 2020-02-18 2022-08-12 创新生物有限公司 伴随诊断用生物标志物组合物及包含其的伴随诊断用试剂盒
WO2021206831A1 (en) * 2020-04-07 2021-10-14 Metanoi Therapeutics, Inc. Ethanolamine formulation for treating epithelial ovarian carcinoma
JP7512433B2 (ja) 2020-05-26 2024-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｄ－１抗体
US20210395366A1 (en) * 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
WO2022025482A1 (ko) * 2020-07-29 2022-02-03 재단법인 아산사회복지재단 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물
JP2023550900A (ja) * 2020-11-02 2023-12-06 アレス トレーディング ソシエテ アノニム がんの組み合わせ治療
CN115607664A (zh) * 2021-07-15 2023-01-17 嘉和生物药业有限公司 抗pd-1抗体在治疗宫颈癌中的应用
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
US20250177505A1 (en) * 2022-02-08 2025-06-05 Korea University Research And Business Foundation Cancer vaccine comprising epitope of c-met and epitope of hif1alpha, and use thereof
AU2024252845A1 (en) 2023-04-06 2025-10-16 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
GB202308807D0 (en) 2023-06-13 2023-07-26 Ionctura Sa Combinations
TW202509063A (zh) * 2023-08-21 2025-03-01 瑞士商百濟神州瑞士有限責任公司 用抗lag3、抗pd-1和化學療法治療食管癌

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp., Seattle, Wash. Bifunktionelle wählbare fusionsgene
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP2360254A1 (en) 1999-08-23 2011-08-24 Dana-Farber Cancer Institute, Inc. Assays for screening anti-pd-1 antibodies and uses thereof
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
AU2002224037A1 (en) 2000-11-15 2002-05-27 Tasuku Honjo Pd-1-lacking mouse and use thereof
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
CA2442066C (en) 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
JP4249013B2 (ja) 2001-07-31 2009-04-02 佑 本庶 Ｐｄ−１に対し特異性を有する物質
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
JP5372500B2 (ja) 2005-06-17 2013-12-18 トレラクス リクイデーティング トラスト Ｉｌｔ３結合分子およびその使用
JP5093097B2 (ja) 2006-03-03 2012-12-05 小野薬品工業株式会社 細胞表面機能分子の細胞外領域多量体
SI2074145T1 (sl) 2006-10-02 2017-12-29 Ac Immune S.A. Humanizirano protitelo proti amiloid beta
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
EP2126087A4 (en) 2007-02-20 2010-10-27 Anaptysbio Inc METHODS FOR PRODUCING PHARMACOTHEQUES, AND USES THEREOF
UA96474C2 (en) 2007-03-20 2011-11-10 Эли Лилли Энд Компани Anti-sclerostin antibodies
EP3173484B1 (en) 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US20120269806A1 (en) 2007-08-21 2012-10-25 The General Hospital Corporation Methods of inducing tolerance
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
RU2571859C2 (ru) 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
ES2548131T3 (es) 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
JP5945096B2 (ja) 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
KR101721707B1 (ko) 2008-11-28 2017-03-30 에모리 유니버시티 감염 및 종양 치료 방법
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
AU2010315304B2 (en) 2009-11-04 2014-03-27 Merck Sharp & Dohme Llc Engineered anti-TSLP antibody
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
CA2790699A1 (en) * 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
WO2011115996A1 (en) 2010-03-17 2011-09-22 Anaptysbio, Inc. Method of producing transcripts using cryptic splice sites
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
US20130217656A1 (en) 2010-08-12 2013-08-22 Beth Israel Deaconess Medical Center Inc Methods and compositions for diagnosing and treating lupus
US20130310266A1 (en) 2010-09-03 2013-11-21 Immport Therapeutics, Inc. Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
WO2012062218A1 (en) 2010-11-11 2012-05-18 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
AU2012228100B2 (en) 2011-03-17 2016-09-08 The University Of Birmingham Re-directed immunotherapy
RU2563346C2 (ru) 2011-03-31 2015-09-20 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
CN102836441B (zh) 2011-06-24 2019-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
CA2873402C (en) 2012-05-15 2023-10-24 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20150079192A1 (en) 2012-05-21 2015-03-19 Marv Enterprises, LLC Treatment of cancer by manipulating the immune system
WO2013174997A1 (en) 2012-05-25 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
KR102129636B1 (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20160119867A (ko) 2014-03-05 2016-10-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
CN113912723A (zh) 2014-03-24 2022-01-11 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
RS60097B1 (sr) 2014-06-19 2020-05-29 Regeneron Pharma Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1
DK3177644T3 (da) 2014-08-05 2021-01-11 MabQuest SA Immunologiske reagenser, som binder til PD-1
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
MA41218A (fr) 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
CA2971734C (en) 2014-12-22 2025-11-18 Enumeral Biomedical Holdings Inc Anti-pd-1 antibodies
MX393750B (es) 2014-12-31 2025-03-24 Checkmate Pharmaceuticals Inc Inmunoterapia antitumoral combinada.
SG11201705323WA (en) 2015-01-16 2017-07-28 Academia Sinica Molecular constructs with targeting and effector elements
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US10508149B2 (en) 2015-04-01 2019-12-17 Anaptysbio, Inc. Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)
KR102740444B1 (ko) * 2015-04-17 2024-12-10 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
DK3478286T3 (da) 2016-06-29 2024-01-29 Tesaro Inc Fremgangsmåder til behandling af ovariecancer
WO2018085468A1 (en) * 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
MX2019005116A (es) 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
EA201990741A1 (ru) 2016-11-29 2019-11-29 Антитела, направленные против белка-1 запрограммированной смерти (pd-1)
US11407830B2 (en) 2017-01-09 2022-08-09 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
US11926665B2 (en) 2017-01-09 2024-03-12 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
TWI852940B (zh) 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法

Also Published As

Publication number Publication date
AU2025200639A1 (en) 2025-02-27
US20200239574A1 (en) 2020-07-30
ES2945745T3 (es) 2023-07-06
ZA201904316B (en) 2022-12-21
US20230111418A1 (en) 2023-04-13
FI3565844T3 (fi) 2023-05-09
BR112019014187A2 (pt) 2020-02-11
US12415855B2 (en) 2025-09-16
IL267804B1 (en) 2024-05-01
US11407830B2 (en) 2022-08-09
AU2018206481A1 (en) 2019-07-25
SG11201906192SA (en) 2019-08-27
EP3565844B1 (en) 2023-03-01
JP7110206B2 (ja) 2022-08-01
EP3565844A1 (en) 2019-11-13
AU2018206481B2 (en) 2025-02-27
TW201831200A (zh) 2018-09-01
KR102606252B1 (ko) 2023-11-23
SG10201913075RA (en) 2020-02-27
CN110382545A (zh) 2019-10-25
EP4219563A3 (en) 2023-10-04
PT3565844T (pt) 2023-05-02
EP3565844B8 (en) 2023-04-12
KR20190114996A (ko) 2019-10-10
MX2019008207A (es) 2019-12-11
JP7110206B6 (ja) 2022-08-25
IL267804B2 (en) 2024-09-01
JP2020504141A (ja) 2020-02-06
PL3565844T3 (pl) 2023-06-12
HUE061842T2 (hu) 2023-08-28
IL267804A (en) 2019-09-26
EP4219563A2 (en) 2023-08-02
TWI767976B (zh) 2022-06-21
WO2018129559A1 (en) 2018-07-12
CA3049440A1 (en) 2018-07-12
JP2022082809A (ja) 2022-06-02
MA47208A (fr) 2019-11-13
DK3565844T3 (da) 2023-05-01

Similar Documents

Publication Publication Date Title
DK3565844T5 (da) Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
DK3455259T3 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
IL259713A (en) Anti-dr5 antibodies and methods of use thereof
DK3394103T3 (da) Kombination af anti-PD-1-antistoffer og bispecifikke anti-CD20-/anti-CD3-antistoffer til cancerbehandling
DK3699198T3 (da) Fremgangsmåder til tumorbehandling ved hjælp af bispecifikke CD3XCD20-antistoffer
PL3551660T3 (pl) Przeciwciała anty-ctla-4 i sposoby ich stosowania
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
EP3244926C0 (en) TREATMENT OF CANCER WITH ANTI-LAP MONOCLONAL ANTIBODIES
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
DK3478286T3 (da) Fremgangsmåder til behandling af ovariecancer
HUE051700T2 (hu) Anti-PD-1 antitestek
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK3142751T3 (da) Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
IL264528B1 (en) Fcrn antibodies and methods of use thereof
DK3810281T3 (da) Fremgangsmåder til behandling af cancer med bispecifikke antI-CD3XMUC16-antistoffer og anti-PD-1-antistoffer
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3292153T3 (da) Kombination af en cd30xcd16a-antistof med en anti-pd-1 antagonistisk antistof til behandling
PT3280440T (pt) Anticorpos anti-c1s humanizados e métodos de utilização destes
DK3134124T3 (da) Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft
DK3661510T3 (da) Fremgangsmåder til behandling af adfærdsændringer